Assembly Biosciences Inc  

(Public, NASDAQ:ASMB)   Watch this stock  
Find more results for NASDAQ:VTUS
23.66
-0.20 (-0.84%)
Apr 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.30 - 24.02
52 week 4.60 - 28.18
Open 23.66
Vol / Avg. 36,157.00/61,723.00
Mkt cap 407.39M
P/E     -
Div/yield     -
EPS -2.57
Shares 17.31M
Beta 0.21
Inst. own 68%

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -44.69% -38.18%
Return on average equity -54.51% -44.57%
Employees 69 -
CDP Score - -

Address

11711 N Meridian St Ste 310
CARMEL, IN 46032-4549
United States - Map
+1-212-5544388 (Phone)
+1-646-7065101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Officers and directors

Derek A. Small President, Chief Executive Officer, Director
Age: 39
Bio & Compensation  - Reuters
David J. Barrett CPA, Chief Financial Officer, Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
Uri Lopatin M.D. Vice President - Research & Development, Chief Medical Officer
Age: 43
Bio & Compensation  - Reuters
William R. Ringo Independent Non-Executive Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Alan James Lewis Ph.D. Director
Age: 70
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 59
Bio & Compensation  - Reuters
Mark Auerbach CPA, Independent Director
Age: 76
Bio & Compensation  - Reuters
Richard DiMarchi Independent Director
Age: 62
Bio & Compensation  - Reuters